Prednisolone benefits community-acquired pneumonia patients

Treatment of patients with community-acquired pneumonia has improved with antibiotics, but it still carries a high risk of morbidity and mortality. Pneumonia causes an excessive release of circulating inflammatory cytokines that can be harmful and cause pulmonary dysfunction. Corticosteroids have anti-inflammatory effects, but previous trials have yielded conflicting data about the benefits of their use in pneumonia.